Centrient joins Almirall hub in Barcelona

10 October 2023

Dutch biosynthetic pharma products specialist Centrient Pharmaceuticals is to open its new innovation lab at Spanish dermatology company Almirall’s (BME: ALM) R&D center in Barcelona.

Centrient, which produces drugs including antibiotics, statins and anti-fungals, will start operations at the lab in the first quarter of 2024 in what has been described as a strategic step in innovation, since it will catalyze the expansion and diversification of the company’s product portfolio while driving the development of sustainable and efficient manufacturing processes.

"The new innovation laboratory is an exhilarating strategic leap for Centrient Pharmaceuticals"Part of the change will see the acceleration of Centrient's evolution from a manufacturer to an innovation partner in the markets it serves.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK